Brigatinib/Brigatinib (Brigatinib) side effects

Clinical trial of Brigatinib/Brigatinib in patients with advanced ALK-positive non-small cell lung cancer who have not previously receivedALK-targeted therapy (ALTA 1L), 33% of treated patients experienced serious adverse reactions. The most common serious adverse reactions were pneumonia, interstitial lung disease (ILD)/pneumonia, fever, dyspnea, pulmonary embolism and fatigue; fatal adverse reactions occurred in 2.9% of patients, including pneumonia, cerebrovascular accident and multiple organ dysfunction syndrome.

In the trial,38% of patients required dose reduction due to adverse reactions, including increased creatine phosphokinase, increased lipase, increased amylase, increased aspartate aminotransferase, interstitial lung disease/pneumonitis, and hypertension; 13% of treated patients permanently discontinued brigatinib due to adverse reactions, including interstitial lung disease/pneumonitis and pneumonitis. Currently, brigatinib is used to treat Huazhihe without causing mutagenic chromosomal damage. Testicular toxicity, reported as reduced seminal vesicle and prostate weight, testicular tubule degeneration, reduced testicular weight and size, with evidence of insufficient embryogenesis.

This original drug is marketed in China under the name brigatinib, and has entered the scope of Class B medical insurance. Specifications The price of 30mg*14 tablets*2 tablets per box may be around 8,000 yuan, which is relatively expensive. Currently, there are relatively cheap generic brigatinib drugs on the market overseas. Their drug ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of a box of 90mg*30 tablets produced by a Bangladesh pharmaceutical factory is around 2,000 yuan (the price may fluctuate due to exchange rates).